May 1, 2021 • Products & Programs / Pharmacy

In the March 2021 issue of Provider News, we advised we would no longer require prior authorization for the following drugs used to treat ocular conditions effective May 1, 2021. Please be advised that prior authorization will continue to be required for these drugs.  We apologize for any inconvenience. 

 

Drug

Code

Code description

*Avastin

C9257

J9035

intravitreal bevacizumab

*Mvasi

Q5107

bevacizumab-awwb

*Zirabev

Q5118

bevacizumab-bvzr

*Non-oncology use is managed by Empire’s medical specialty drug review team.

 

1160-0521-PN-NY

 


Featured In:
May 2021 Newsletter